Trading Update

RNS Number : 8466B

Allergy Therapeutics PLC

12 January 2015

 



12 January 2015

Allergy Therapeutics plc

("Allergy Therapeutics"or the 'Company")

Trading Update

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its unaudited interim results for the 6 months ended 31 December 2014 on 2 March 2015.

The Company expects to report revenue growth of 11% for the period at constant currency, with first half revenues of approximately £30.2m (H1 2014: £27.2m).  This double digit sales growth has been driven primarily by the Company's improving trading performance as it continues to increase its market share in all of its main markets.

First half reported revenues are expected to be approximately £28.2m (H1 2014: £27.2m), representing growth of 4% taking into account currency impacts; the negative impact from the weakening Euro being £2.0m.

Manuel Llobet, Chief Executive Officer, said:

"Despite flat markets, we have been able to grow double digit at constant currency by increasing our market share, particularly in Germany and the Netherlands, thanks to our winning range of short course aluminium free allergy vaccines."

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Panmure Gordon	[phone]
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
FTI Consulting	[phone]
Simon Conway
Victoria Foster Mitchell

Note to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

 

END

 

 

TSTLIFVILEIFLIE